Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 1:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 978 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Metformin (glucophage) Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

NCT01809327
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin 100 mg, Canagliflozin 300 mg, Metformin XR
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encinitas, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 8, 2026, 1:01 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

NCT00900146
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canakinumab, Metformin, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
18
States / cities
Phoenix, Arizona • La Jolla, California • Los Gatos, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Oct 8, 2026, 1:01 AM EDT
Completed Phase 2 Interventional

A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes

NCT00871936
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
SLx-4090, Placebo, Metformin
Drug · Other
Lead sponsor
Response Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Anaheim, California • Burbank, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 8, 2026, 1:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults

NCT07066722
View directory record Official record
Conditions
HIV Infections
Interventions
VH4524184, Itraconazole, Rifabutin, Phenytoin, Metformin, Digoxin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 8, 2026, 1:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Preventing Diabetes in the Deep South: Extending Partnerships and Adapting Interventions to Reach Rural Communities at High Risk.

NCT04343872
View directory record Official record
Conditions
Pre-diabetes
Interventions
Receive lifestyle modification alone, Metformin therapy
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 8, 2026, 1:01 AM EDT
Terminated Early Phase 1 Interventional Results available

Cardiometabolic Disease and Pulmonary Hypertension

NCT03349775
View directory record Official record
Conditions
Obesity
Interventions
Metformin, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 8, 2026, 1:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Lazertinib (JNJ-73841937) in Healthy Participants

NCT05076877
View directory record Official record
Conditions
Healthy
Interventions
Lazertinib, Midazolam, Rosuvastatin, Metformin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 8, 2026, 1:01 AM EDT
Not listed No phase listed Observational

Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)

NCT03627039
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
SGLT2, Metformin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 8, 2026, 1:01 AM EDT
Completed Phase 3 Interventional Results available

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

NCT03429543
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Metformin, Insulin, Placebo, Linagliptin, Empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
10 Years to 17 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
44
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 8, 2026, 1:01 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes

NCT01849289
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin Degludec, Insulin Glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
18
States / cities
Anaheim, California • Lomita, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 8, 2026, 1:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Levoketoconazole and Metformin

NCT03880825
View directory record Official record
Conditions
Healthy Subjects
Interventions
Metformin 500 mg Oral Tablet, Levoketoconazole 150 - 600 mg (BID)
Drug
Lead sponsor
Cortendo AB
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Oct 8, 2026, 1:01 AM EDT
Completed Not applicable Interventional

Effect of NNS on Metformin/GDF15, Pilot

NCT05400863
View directory record Official record
Conditions
Obesity, Adolescent, Pre Diabetes
Interventions
avoid sugary and NNS drinks plus start Metformin, avoid sugary drinks (allowed water and drinks sweetened with NNS) plus start Metformin
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
10 Years to 21 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 8, 2026, 1:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration

NCT02911792
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Metformin, Glipizide 5 MG
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
30 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 8, 2026, 1:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Genetics on Metformin Pharmacokinetics

NCT00187798
View directory record Official record
Conditions
Other Conditions That May Be A Focus of Clinical Attention
Interventions
Metformin HCl
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Oct 8, 2026, 1:01 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Hyperemesis Gravidarum Risk Reduction With Metformin

NCT07129473
View directory record Official record
Conditions
Hyperemesis Gravidarum
Interventions
Metformin Extended Release Oral Tablet
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
2
States / cities
Birmingham, Alabama • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 8, 2026, 1:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting

NCT00835497
View directory record Official record
Conditions
Healthy
Interventions
5 mg/500 mg Glipizide Metformin Hydrochloride Tablets, 5 mg/500 mg METAGLIP™ Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Oct 8, 2026, 1:01 AM EDT
Recruiting Phase 4 Interventional

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

NCT06445946
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Pregnancy, High Risk
Interventions
Metformin, Insulin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
1,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
26
States / cities
Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 8, 2026, 1:01 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy

NCT01240759
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
S-707106 Dose A, S-707106 Dose B, S-707106 Dose C, Placebo A tablet, Metformin
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 8, 2026, 1:01 AM EDT
Completed Phase 3 Interventional Results available

Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00518882
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, exenatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
61
States / cities
Birmingham, Alabama • Goodyear, Arizona • Artesia, California + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 8, 2026, 1:01 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

NCT04596631
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Oral semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 8, 2026, 1:01 AM EDT
Terminated Phase 1 Interventional

Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions

NCT05536037
View directory record Official record
Conditions
Erythroplakia, Leukoplakia, Oral Cavity Carcinoma, Proliferative Verrucous Leukoplakia
Interventions
Metformin, Biopsy
Drug · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 8, 2026, 1:01 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients

NCT01579812
View directory record Official record
Conditions
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Interventions
Metformin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
19 Years to 79 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 8, 2026, 1:01 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents

NCT03285594
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin, Insulin glargine (HOE901), Placebo, Oral Antidiabetes Drugs (OADs)
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Huntington Park, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 8, 2026, 1:01 AM EDT
Completed Phase 2 Interventional

A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

NCT00423501
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Woodstock, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 8, 2026, 1:01 AM EDT